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referred  to as  “the $1,000 genomes,  the $100,000 analysis” 
problem (9), will only continue to grow.
Tumor heterogeneity. Variation between patients is often referred 














































































































Different study designs for array-based gene expression studies. (A) Studies aimed at identifying different subgroups investigate a mixed popula-
tion of patients to group tumors with similar alterations together, and markers that recognize each type can then be identified. (B) This in contrast 
to studies that search for markers for prediction of therapy response or outcome; here, selected groups of patients are analyzed to identify the 
most discriminating alterations.
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Subtypes of breast cancer. Hypothetically, subtypes of breast cancer can be viewed as a spectrum of more or less related entities. The major-
ity are classified through histopathology as IDC NOS, but some types have defined histopathological traits. Such groups have tumors that are 
frequently either ER–/HER2– or ER+/HER2–, which also corresponds to the outer part of a spectrum of intrinsic subtypes, namely the basal-like 
and luminal A types of breast cancer. NGS of a basal-like (top), a HER2-related (second from top), a luminal B (third from top), and a luminal A 
tumor (bottom) show distinct structural characteristics. The circos plots show intrachromosomal rearrangements in green and interchromosomal 
rearrangements in purple (circos plots used with permission from Nature; ref. 43).
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Hypothetical models explaining intratumor heterogeneity. (A–C) Different models of tumor progression can give rise to distinct types of intratumor 
heterogeneity, exemplified here by the clonal evolution (A), the cancer stem cell (B), and the mutator phenotype (C) models. (D) The different 
models can result in distinct spatial distributions of subpopulations.
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A multilevel approach for a dynamic classifica-
tion system. The first level is defined by tumor 
and patient characteristics. The second level 
includes detailed genomic and translational 
analyses of tumor to define molecular type 
and selection of appropriate tests. Parallel 
to that, tumor-specific serum markers can be 
assessed. The third level determines intratu-
mor heterogeneity and is crucial for selection 
of appropriate markers for micrometastatic 
disease detection in serum, bone marrow, or 
lymph nodes. MRD, minimal residual disease. 
The fourth level integrates all available infor-
mation to produce a diagnosis, prognostica-
tion, prediction of therapy, and program for 
disease monitoring.
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Clinical decision making in the era of NGS
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